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Interleukin 1 and its receptors are associated with allergic diseases such as asthma. In the present study, we
measured DNA methylation at the IL1R1 and IL1R2 gene loci and assessed for associations with asthma-related
phenotypes and gene expressions. We found that asthmatic and atopic individuals have higher IL1R2 promoter
DNA methylation than control subjects. Additionally, we observed a negative correlation between DNA methylation
at the IL1R2 promoter and IL1R2 mRNA expression. These results suggest for the first time that IL1R2 promoter DNA
methylation is associated with its gene repression in allergic diseases such as asthma.
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Interleukin 1 (IL1) plays a key role in the inflammatory
process of asthma [1]. We reported the association of
polymorphisms within the IL1 receptors type I (IL1R1)
and type II (IL1R2) gene loci with asthma and atopy in
the French Canadian Saguenay–Lac-Saint-Jean (SLSJ)
asthma study [2, 3]. The IL1R2 gene expression signa-
ture in allergic asthma has also been described [4–6].
Epigenetics has received tremendous attention, and vari-
ations in DNA methylation (DNA-Me) in candidate
genes have been reported associated with asthma and al-
lergic related disorders [7–12]. These findings underline
the relevance of genetic and epigenetic profiling to iden-
tify pathways associated with allergic diseases. Such a
combined approach will facilitate the understanding of
the functional impacts of genetic and epigenetic varia-
tions on transcription and molecular mechanisms in-
volved in allergic diseases. In this study, we hypothesized
that DNA-Me in the promoters of IL1R1 and IL1R2 is
associated with asthma and/or atopy.Clinical characteristics and methods
Clinical characteristics of the 93 individuals (21 non-
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from the Saguenay–Lac-Saint-Jean asthma familial col-
lection [13] and included in the analysis are shown in
Table 1. Ethics committee approved the study, and all
subjects gave informed consent. Based on previous gen-
etic [14] and epigenetic analyses [15], methylation at 1
CpG in promoter and 3 CpGs in exon 1 of IL1R1
(Additional file 1: Figure S1) and 5 CpGs in promoter
of IL1R2 (Fig. 1a) was measured. DNA-Me differences
(Δβ) between affected (individuals with asthma, atopy,
or both) and non-affected individuals were assessed
and DNA-Me was correlated with gene expression for
each CpG. DNA-Me was measured on DNA extracted
from blood (Blood and Cell Culture DNA Midi Kit, Qiagen,
Canada) using bis-pyrosequencing (EpiTech Bisulfite Kits,
Pyromark PCR Kit, Pyromark Gold Q24 Reagents, Qiagen,
Canada). PCR primers were designed using PyroMark
Assay Design software (v2.0.1.15) (Qiagen,Canada). Total
RNA was extracted from whole blood (RNeasy Plus Mini
Kit, Qiagen, Canada) using a subset of affected and non-
affected individuals (n = 30). For each sample, RNA was
converted into cDNA (qScript™ cDNA SuperMix, Quanta
Biosciences, USA), and mRNA quantification was deter-
mined (PerfeCTa® qPCR FastMix®, Quanta Biosciences,
USA) using the two standard curves method with RPLP0 as
a reference gene [16].
The association between IL1R1 and IL1R2 DNA-Me
levels and asthma and/or atopy at each CpG wasis article is distributed under the terms of the Creative Commons
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
um, provided you give appropriate credit to the original author(s) and the
ons license, and indicate if changes were made. The Creative Commons
eativecommons.org/publicdomain/zero/1.0/) applies to the data made
ted.
Table 1 Clinical characteristics of individuals from the Saguenay–Lac-Saint-Jean asthma familial collection
Characteristics All individuals (n = 93) Controls (n = 25) Asthmaticsa and/
or atopicsb (n = 68)
Sex ratio (M:F) 1:1.2 1:1.8 1:1
Mean age, year (range) 15 (3–46) 14 (3–44) 15 (4–46)
<16 years old, n (%) 64 (69) 18 (72) 46 (68)
FEV1, % predicted (SD)
c 62 (40) 63 (40) 62 (40)
PC20, mg/ml (SD)
d 8.2 (4.3) 15.3 (3.4) 6.8 (4.4)
Serum IgE, μg/l (SD)e 109 (5) 36 (4) 157 (4)
Asthma, n (%)a 47 (51) NA 47 (69)
Atopy, n (%)b 47 (51) NA 47 (69)
With asthma, n (%)a 26 (28) NA 26 (38)
aPresent asthma or past documented clinical history of asthma. Data available for all individuals
bDefined as having at least one positive response on the skin prick test (wheal diameter ≥3 mm at 10 min). Data available for all individuals
cFEV1 =mean and standard deviation (SD) calculated for forced expiratory volume in 1 s for 67 individuals (16 controls, 51 asthmatic and/or atopic individuals)
dPC20 = geometric mean and SD of provocative methacholine concentration inducing 20 % decline in FEV1 calculated for 58 individuals (14 controls, 44 asthmatic
and/or atopic individuals)
eIgE = geometric mean and SD of serum immunoglobulin (Ig) E level concentration calculated for 80 individuals (20 controls, 60 asthmatic and/or
atopic individuals)
Fig. 1 Association between CpGs’ DNA methylation levels for IL1R2 and gene expression in asthma and atopy. a Schematic representation of
IL1R2, location of epigenotyped CpG sites, and pairwise correlations between CpG sites. b Mean DNA-Me levels for CpG2 and CpG3-4 of IL1R2
in control and affected subjects (individuals with asthma, atopy, or both). c Correlation between DNA-Me level of IL1R2-CpG2 and mRNA level.
d Correlation between mean DNA-Me level of IL1R2-CpG3 and 4 and mRNA level
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Table 2 Summary of DNA methylation analysis on promoter of
two interleukin 1 receptors in whole blood samples from
Saguenay–Lac-Saint-Jean asthma familial collection
Gene CpG Δβa p value
IL1R1 promoter and exon 1 1 1.19 0.113
2–4 0.22 0.892




Significant p values are shown in italics
aΔβ are calculated with mean methylation ratio for asthmatic and/or atopic
individuals on control individuals
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covariates [9]. Gene expression analysis by phenotype was
not performed as control group sample size was insuffi-
cient (n = 4). The association between DNA-Me and
mRNA levels was assessed by Spearman correlation. CpG
dinucleotides with r > 0.6 were combined before they were
tested for associations with asthma and/or atopy and for
correlation with gene expressions. Δβ with p value < 0.05
was considered statistically significant. Statistical analyses
were conducted using the statistical software SPSS
(v11.5.0, IBM, USA).
Results
In this study, we detected higher levels of DNA-Me at
IL1R2 among affected individuals (i.e., with asthma,
atopy, or both) as compared to non-affected controls
(Δβ = 8.02 %, p value = 0.013, and Δβ = 3.72 %, p value =
0.012 for IL1R2-CpG2 and the mean for CpG3 and
CpG4, respectively (Table 2, Fig. 1b)). Atopic and non-
atopic asthma were associated with DNA-Me at IL1R2
but not atopy alone (data not shown). We also observed
that DNA-Me at IL1R2-CpG2 was negatively correlated
with its mRNA levels (r = −0.511, p value = 0.004)
(Fig. 1c), but it was not correlated for CpG3 and CpG4
(Fig. 1d).
Discussion
An epigenetic signature has also been identified for
IL1R2 promoter in systemic lupus erythematosus (SLE)
[15]. The risk of allergic disorders was significantly in-
creased in SLE patients, which suggests that these condi-
tions share some common biomarkers [17]. The
negative correlation we observed between DNA-Me and
gene expression levels for IL1R2 may be due to stoichi-
ometry. Methylation may limit access of a transcription
factor to DNA and hinders transcriptions [18]. We iden-
tified potential binding sites for transcription factors
relevant to asthma near the CpG dinucleotide sites of
IL1R2 analyzed (Additional file 2: Figure S2) which could
explain the inverse correlation between methylation andgene expression [19]. Noteworthy is the potential bind-
ing site for nuclear factor kappa B/c-rel (NFKB) at the
IL1R2 promoter; it is involved in inflammation through
several pathways, including IL1 signalization [20]. Given
that IL1R2 acts as a decoy receptor to antagonize the
bound ligand [21], our data prompted the speculation
that hypermethylation of IL1R2 in asthma and atopy
negatively regulates IL1R2 expression and less decoy
receptors are available to reduce the downstream pro-
inflammatory response of IL1 in the presence of un-
changed IL1R1 level [22, 23]. Unlike IL1R1, IL1R2 does
not have an intracellular domain and the formation of
IL1-IL1R2 complex inactivates the IL1 downstream sig-
naling cascade; hence, silences the role of IL1 in inflam-
mation. Functional study will be needed to investigate
the impact of observed epi-variations on the production
of expressed receptors. This hypothesis could be attrib-
uted to both asthma and atopy as IL1R2 non-signaling
receptor is suspected to influence Th2 imbalance [24],
and both disorders are driven by Th2 allergic lung in-
flammation [25, 26].
To our knowledge, this is the first report of (1) a
hypermethylation signature of IL1R2 promoter in
asthma with or without atopy and (2) an inverse correl-
ation between methylation at IL1R2 promoter and its
gene expression. Together, they underline the relevance
of IL1R2 as a potential biomarker of asthma and atopy.
Further work is needed to understand the interactions
between environmental exposures and epigenetic modi-
fications like the ones identified in this study. Such un-
derstanding will aid the discovery of disease mechanisms
associated and development of more effective therapies.Additional files
Additional file 1: Figure S1. Schematic representation of IL1R1 and
location of epigenotyped CpG sites. This figure illustrates a simplified
schematic representation of IL1R1 and location of selected CpG
dinucleotide sites and pairwise correlations between each CpG.
Additional file 2: Figure S2. Potential binding sites for transcription
factors in IL1R1 and IL1R2. This figure shows a segment of the primary
sequences of IL1R1 and IL1R2. Both sequences lie in the respective gene
promoter (UCSC Genome Browser assembly GRCh38/hg38).
Epigenotyped CpG sites are shown in blue and are numbered from the
distal part of the promoter. Exons are shown in red. Potential binding
sites for transcription factors in differentially methylated loci are shown
by underlined sequences, and the name of the transcription factors are
indicated underneath.Abbreviations
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